Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alectinib neoadjuvant therapy for ALK-positive stage III non-small cell lung cancer
2020-003432-25Phase 2Active
- Sponsor
- Gruppo Oncologico Italiano di Ricerca Clinica
- Start
- Aug 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of alectinib in non-small cell lung cancer (NSCLC), sponsored by Gruppo Oncologico Italiano di Ricerca Clinica. Primary endpoint: Major pathologic response. Started Aug 2021; status: active.
02
Drugs
alectinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2020-003432-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-003432-25.